Eli Lilly and Merck & Co. are partnering with Purdue University to launch the Young Institute Pharmaceutical Manufacturing ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year.

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

(Bloomberg) -- Doctors may change how they treat liver cancer after drugs from AstraZeneca Plc and Merck & Co. helped some patients, marking the first treatment progress for them in decades.

China’s drug regulator approved Merck & Co.’s blockbuster HPV vaccine for use by men, opening a new untapped market for the ...

The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

Key Takeaways Merck faces headwinds like declining sales of the HPV vaccine, Gardasil, and diabetes drug, Januvia. Merck ...